A detailed history of Nuveen Asset Management, LLC transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 1,322,122 shares of IOVA stock, worth $10.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,322,122
Previous 1,328,117 0.45%
Holding current value
$10.8 Million
Previous $10.7 Million 16.55%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.28 - $11.9 $43,643 - $71,340
-5,995 Reduced 0.45%
1,322,122 $12.4 Million
Q2 2024

Aug 09, 2024

SELL
$7.78 - $14.19 $2.54 Million - $4.63 Million
-326,555 Reduced 19.74%
1,328,117 $10.7 Million
Q1 2024

May 13, 2024

BUY
$7.59 - $17.47 $5.38 Million - $12.4 Million
708,780 Added 74.93%
1,654,672 $24.5 Million
Q4 2023

Feb 14, 2024

SELL
$3.3 - $8.89 $2.17 Million - $5.85 Million
-657,585 Reduced 41.01%
945,892 $7.69 Million
Q3 2023

Nov 14, 2023

SELL
$4.44 - $8.79 $2.78 Million - $5.5 Million
-625,804 Reduced 28.07%
1,603,477 $7.3 Million
Q2 2023

Aug 14, 2023

BUY
$5.36 - $9.06 $395,241 - $668,075
73,739 Added 3.42%
2,229,281 $15.7 Million
Q1 2023

May 15, 2023

BUY
$5.53 - $8.22 $4.47 Million - $6.65 Million
808,623 Added 60.04%
2,155,542 $13.2 Million
Q4 2022

Feb 14, 2023

SELL
$5.62 - $10.0 $2.2 Million - $3.91 Million
-391,466 Reduced 22.52%
1,346,919 $8.61 Million
Q3 2022

Nov 14, 2022

SELL
$9.53 - $13.11 $573,362 - $788,750
-60,164 Reduced 3.35%
1,738,385 $16.7 Million
Q2 2022

Aug 15, 2022

BUY
$6.38 - $18.33 $8.5 Million - $24.4 Million
1,332,772 Added 286.14%
1,798,549 $19.9 Million
Q1 2022

May 16, 2022

SELL
$12.38 - $19.1 $2.62 Million - $4.04 Million
-211,430 Reduced 31.22%
465,777 $6.99 Million
Q4 2021

Feb 14, 2022

BUY
$16.55 - $27.63 $1.02 Million - $1.71 Million
61,929 Added 10.07%
677,207 $12.9 Million
Q3 2021

Nov 12, 2021

SELL
$20.35 - $26.63 $207,142 - $271,066
-10,179 Reduced 1.63%
615,278 $15.2 Million
Q2 2021

Aug 16, 2021

BUY
$16.33 - $33.07 $169,815 - $343,894
10,399 Added 1.69%
625,457 $16.3 Million
Q1 2021

May 17, 2021

SELL
$28.67 - $52.59 $1.33 Million - $2.44 Million
-46,304 Reduced 7.0%
615,058 $19.5 Million
Q4 2020

May 17, 2021

BUY
$28.04 - $50.26 $943,854 - $1.69 Million
33,661 Added 5.36%
661,362 $30.7 Million
Q4 2020

Feb 16, 2021

BUY
$28.04 - $50.26 $1.53 Million - $2.75 Million
54,702 Added 9.55%
627,701 $29.1 Million
Q3 2020

Nov 16, 2020

BUY
$27.75 - $36.3 $508,574 - $665,270
18,327 Added 3.3%
572,999 $18.9 Million
Q2 2020

Aug 14, 2020

SELL
$27.21 - $41.0 $6.42 Million - $9.67 Million
-235,831 Reduced 29.83%
554,672 $15.2 Million
Q1 2020

May 14, 2020

BUY
$19.54 - $38.85 $2.8 Million - $5.57 Million
143,313 Added 22.14%
790,503 $23.7 Million
Q4 2019

Feb 14, 2020

SELL
$17.95 - $29.41 $1.9 Million - $3.11 Million
-105,749 Reduced 14.04%
647,190 $17.9 Million
Q3 2019

Nov 14, 2019

BUY
$17.99 - $26.0 $666,187 - $962,806
37,031 Added 5.17%
752,939 $13.7 Million
Q2 2019

Aug 15, 2019

BUY
$9.78 - $24.52 $6.66 Million - $16.7 Million
680,922 Added 1946.27%
715,908 $17.6 Million
Q1 2019

May 14, 2019

BUY
$8.41 - $11.26 $294,232 - $393,942
34,986 New
34,986 $333,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.29B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.